New pill could ease stiffness and pain for ankylosing spondylitis patients
NCT ID NCT07172360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether VC005 tablets can reduce symptoms of active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 420 adults aged 18 to 70 will receive either VC005 or a placebo for 48 weeks. The main goal is to see how many achieve a 20% improvement in disease activity after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VC005 tablets
- What this could lead to
- If successful, this could provide a new oral treatment option to control symptoms and slow disease progression in people with active ankylosing spondylitis.
- What could go wrong
- This is still an experimental drug. Phase 3 trials can fail to show enough benefit or reveal unexpected side effects. The results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.